SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
© 2023. The Author(s)..
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml-1). Vaccine failure rates were highest in ANCA-associated vasculitis on rituximab (21/29, 72%), hemodialysis on immunosuppressive therapy (6/30, 20%) and solid organ transplant recipients (20/81, 25% and 141/458, 31%). SARS-CoV-2-specific T cell responses were detected in 513 of 580 (88%) patients, with lower T cell magnitude or proportion in hemodialysis, allogeneic hematopoietic stem cell transplantation and liver transplant recipients (versus healthy controls). Humoral responses against Omicron (BA.1) were reduced, although cross-reactive T cell responses were sustained in all participants for whom these data were available. BNT162b2 was associated with higher antibody but lower cellular responses compared to ChAdOx1 nCoV-19 vaccination. We report 474 SARS-CoV-2 infection episodes, including 48 individuals with hospitalization or death from COVID-19. Decreased magnitude of both the serological and the T cell response was associated with severe COVID-19. Overall, we identified clinical phenotypes that may benefit from targeted COVID-19 therapeutic strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 7 vom: 15. Juli, Seite 1760-1774 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barnes, Eleanor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 21.07.2023 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02414-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359160069 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359160069 | ||
| 003 | DE-627 | ||
| 005 | 20240320233243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02414-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM359160069 | ||
| 035 | |a (NLM)37414897 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barnes, Eleanor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels (<380 AU ml-1). Vaccine failure rates were highest in ANCA-associated vasculitis on rituximab (21/29, 72%), hemodialysis on immunosuppressive therapy (6/30, 20%) and solid organ transplant recipients (20/81, 25% and 141/458, 31%). SARS-CoV-2-specific T cell responses were detected in 513 of 580 (88%) patients, with lower T cell magnitude or proportion in hemodialysis, allogeneic hematopoietic stem cell transplantation and liver transplant recipients (versus healthy controls). Humoral responses against Omicron (BA.1) were reduced, although cross-reactive T cell responses were sustained in all participants for whom these data were available. BNT162b2 was associated with higher antibody but lower cellular responses compared to ChAdOx1 nCoV-19 vaccination. We report 474 SARS-CoV-2 infection episodes, including 48 individuals with hospitalization or death from COVID-19. Decreased magnitude of both the serological and the T cell response was associated with severe COVID-19. Overall, we identified clinical phenotypes that may benefit from targeted COVID-19 therapeutic strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Goodyear, Carl S |e verfasserin |4 aut | |
| 700 | 1 | |a Willicombe, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Gaskell, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Siebert, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a I de Silva, Thushan |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Sam M |e verfasserin |4 aut | |
| 700 | 1 | |a Rea, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Snowden, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Miles |e verfasserin |4 aut | |
| 700 | 1 | |a Pirrie, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Bowden, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Dunachie, Susanna J |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Zixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Satsangi, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Pope, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Molly |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Sean H |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Klenerman, Paul |e verfasserin |4 aut | |
| 700 | 0 | |a PITCH consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Basu, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Gilmour, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Irwin, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Meacham, Georgina |e verfasserin |4 aut | |
| 700 | 1 | |a Marjot, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Dimitriadis, Stavros |e verfasserin |4 aut | |
| 700 | 1 | |a Kelleher, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Prendecki, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Candice |e verfasserin |4 aut | |
| 700 | 1 | |a Mortimer, Paige |e verfasserin |4 aut | |
| 700 | 1 | |a McIntyre, Stacey |e verfasserin |4 aut | |
| 700 | 1 | |a Selby, Rachael |e verfasserin |4 aut | |
| 700 | 1 | |a Meardon, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Dung |e verfasserin |4 aut | |
| 700 | 1 | |a Tipton, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Longet, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Laidlaw, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Orchard, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Ireland, Georgina |e verfasserin |4 aut | |
| 700 | 0 | |a CONSENSUS |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kearns, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkham, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a McInnes, Iain B |e verfasserin |4 aut | |
| 700 | 0 | |a OCTAVE Collaborative Group |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Alex G |e investigator |4 oth | |
| 700 | 1 | |a Mentzer, Alex |e investigator |4 oth | |
| 700 | 1 | |a Deeks, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Jamsen, Anni |e investigator |4 oth | |
| 700 | 1 | |a Brown, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Conlon, Chris |e investigator |4 oth | |
| 700 | 1 | |a Dold, Chris |e investigator |4 oth | |
| 700 | 1 | |a Duncan, Christopher J A |e investigator |4 oth | |
| 700 | 1 | |a Skelly, Donal |e investigator |4 oth | |
| 700 | 1 | |a Kronsteiner, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Abraham, Priyanka |e investigator |4 oth | |
| 700 | 1 | |a Phillips, Eloise |e investigator |4 oth | |
| 700 | 1 | |a Jeffery, Katie |e investigator |4 oth | |
| 700 | 1 | |a Turtle, Lance |e investigator |4 oth | |
| 700 | 1 | |a Frending, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Stafford, Lizzie |e investigator |4 oth | |
| 700 | 1 | |a Ali, Mohammad |e investigator |4 oth | |
| 700 | 1 | |a Rongkard, Patpong |e investigator |4 oth | |
| 700 | 1 | |a Payne, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Adele, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Travis, Simon |e investigator |4 oth | |
| 700 | 1 | |a Gardiner, Siobhan |e investigator |4 oth | |
| 700 | 1 | |a Dobson, Sue L |e investigator |4 oth | |
| 700 | 1 | |a Malone, Tom |e investigator |4 oth | |
| 700 | 1 | |a Bibi, Sagida |e investigator |4 oth | |
| 700 | 1 | |a Carroll, Miles |e investigator |4 oth | |
| 700 | 1 | |a Faustini, Sian |e investigator |4 oth | |
| 700 | 1 | |a Foulkes, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Frater, John |e investigator |4 oth | |
| 700 | 1 | |a Hall, Victoria |e investigator |4 oth | |
| 700 | 1 | |a Hopkins, Susan |e investigator |4 oth | |
| 700 | 1 | |a Islam, Jasmin |e investigator |4 oth | |
| 700 | 1 | |a Lambe, Teresa |e investigator |4 oth | |
| 700 | 1 | |a Longet, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Moore, Shona C |e investigator |4 oth | |
| 700 | 1 | |a Otter, Ashley |e investigator |4 oth | |
| 700 | 1 | |a Rowland-Jones, Sarah L |e investigator |4 oth | |
| 700 | 1 | |a Thaventhir, James E D |e investigator |4 oth | |
| 700 | 1 | |a Wootton, Daniel G |e investigator |4 oth | |
| 700 | 1 | |a Brown, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Amirthalingam, Gayatri |e investigator |4 oth | |
| 700 | 1 | |a Beesley, Richard |e investigator |4 oth | |
| 700 | 1 | |a Churchill, Vicky |e investigator |4 oth | |
| 700 | 1 | |a Loughton, Holly |e investigator |4 oth | |
| 700 | 1 | |a Insch, Elspeth |e investigator |4 oth | |
| 700 | 1 | |a MacDonald, Eilean |e investigator |4 oth | |
| 700 | 1 | |a Middleton, Gary |e investigator |4 oth | |
| 700 | 1 | |a Billingham, Lucinda |e investigator |4 oth | |
| 700 | 1 | |a Lowe, Faye |e investigator |4 oth | |
| 700 | 1 | |a Magwaro, Sophia |e investigator |4 oth | |
| 700 | 1 | |a Al-Taei, Saly |e investigator |4 oth | |
| 700 | 1 | |a Arnott, Maxine |e investigator |4 oth | |
| 700 | 1 | |a Bennett, Louise |e investigator |4 oth | |
| 700 | 1 | |a Brock, James |e investigator |4 oth | |
| 700 | 1 | |a Keillor, Victora |e investigator |4 oth | |
| 700 | 1 | |a Melville, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Melville, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Miller, Samantha |e investigator |4 oth | |
| 700 | 1 | |a Najm, Aurelie |e investigator |4 oth | |
| 700 | 1 | |a Paterson, Caron |e investigator |4 oth | |
| 700 | 1 | |a Rodgers, Lewis |e investigator |4 oth | |
| 700 | 1 | |a Rutherford, Matthew |e investigator |4 oth | |
| 700 | 1 | |a Rundell, Suzann |e investigator |4 oth | |
| 700 | 1 | |a Smith, Emily |e investigator |4 oth | |
| 700 | 1 | |a Stewart, Lynn |e investigator |4 oth | |
| 700 | 1 | |a Sunzini, Flavia |e investigator |4 oth | |
| 700 | 1 | |a Tong, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Woolcock, Kieran |e investigator |4 oth | |
| 700 | 1 | |a Basheer, Faisal |e investigator |4 oth | |
| 700 | 1 | |a Crawley, Charles |e investigator |4 oth | |
| 700 | 1 | |a Malladi, Ram |e investigator |4 oth | |
| 700 | 1 | |a King, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Lockey, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Uttenthal, Ben |e investigator |4 oth | |
| 700 | 1 | |a Koh, Mickey B C |e investigator |4 oth | |
| 700 | 1 | |a Hansford, Sam |e investigator |4 oth | |
| 700 | 1 | |a Sandhar, Gurjinder |e investigator |4 oth | |
| 700 | 1 | |a Kesavan, Murali |e investigator |4 oth | |
| 700 | 1 | |a Moore, Celia |e investigator |4 oth | |
| 700 | 1 | |a Manousou, Pinelopi |e investigator |4 oth | |
| 700 | 1 | |a Hahn, Gareth |e investigator |4 oth | |
| 700 | 1 | |a Mullish, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Atta, Maria |e investigator |4 oth | |
| 700 | 1 | |a Gleeson, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Lightstone, Liz |e investigator |4 oth | |
| 700 | 1 | |a Martin, Paul |e investigator |4 oth | |
| 700 | 1 | |a McAdoo, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Thomson, Tina |e investigator |4 oth | |
| 700 | 1 | |a Avenoso, Daniele |e investigator |4 oth | |
| 700 | 1 | |a Sanderson, Robin |e investigator |4 oth | |
| 700 | 1 | |a Taylor, Claire |e investigator |4 oth | |
| 700 | 1 | |a Bhandal, Khushpreet |e investigator |4 oth | |
| 700 | 1 | |a Hull, Diana |e investigator |4 oth | |
| 700 | 1 | |a Trivedi, Palak |e investigator |4 oth | |
| 700 | 1 | |a Filer, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Hurst, Erin |e investigator |4 oth | |
| 700 | 1 | |a Publicover, Amy |e investigator |4 oth | |
| 700 | 1 | |a Scouse, Katy |e investigator |4 oth | |
| 700 | 1 | |a Chalk, Jem |e investigator |4 oth | |
| 700 | 1 | |a Hanke, Daniel |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 7 vom: 15. Juli, Seite 1760-1774 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:7 |g day:15 |g month:07 |g pages:1760-1774 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02414-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 7 |b 15 |c 07 |h 1760-1774 | ||